Paclitaxel, UFT, and calcium folinate in metastatic breast cancer

Natalie R. Dickson, Brenda P. Nicholson, Kenneth Hande, Charles Blanke, David Johnson, Alan Cohen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.

Original languageEnglish (US)
Pages (from-to)69-70
Number of pages2
JournalOncology
Volume13
Issue number7 SUPPL.
StatePublished - 1999

Fingerprint

Leucovorin
Paclitaxel
Breast Neoplasms
Hand-Foot Syndrome
Tegafur
Maximum Tolerated Dose
Uracil
Hypotension
Vomiting
Diarrhea

ASJC Scopus subject areas

  • Oncology

Cite this

Dickson, N. R., Nicholson, B. P., Hande, K., Blanke, C., Johnson, D., & Cohen, A. (1999). Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. Oncology, 13(7 SUPPL.), 69-70.

Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. / Dickson, Natalie R.; Nicholson, Brenda P.; Hande, Kenneth; Blanke, Charles; Johnson, David; Cohen, Alan.

In: Oncology, Vol. 13, No. 7 SUPPL., 1999, p. 69-70.

Research output: Contribution to journalArticle

Dickson, NR, Nicholson, BP, Hande, K, Blanke, C, Johnson, D & Cohen, A 1999, 'Paclitaxel, UFT, and calcium folinate in metastatic breast cancer', Oncology, vol. 13, no. 7 SUPPL., pp. 69-70.
Dickson NR, Nicholson BP, Hande K, Blanke C, Johnson D, Cohen A. Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. Oncology. 1999;13(7 SUPPL.):69-70.
Dickson, Natalie R. ; Nicholson, Brenda P. ; Hande, Kenneth ; Blanke, Charles ; Johnson, David ; Cohen, Alan. / Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. In: Oncology. 1999 ; Vol. 13, No. 7 SUPPL. pp. 69-70.
@article{2355eb3bf52d406f971cb7db94335852,
title = "Paclitaxel, UFT, and calcium folinate in metastatic breast cancer",
abstract = "This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.",
author = "Dickson, {Natalie R.} and Nicholson, {Brenda P.} and Kenneth Hande and Charles Blanke and David Johnson and Alan Cohen",
year = "1999",
language = "English (US)",
volume = "13",
pages = "69--70",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Paclitaxel, UFT, and calcium folinate in metastatic breast cancer

AU - Dickson, Natalie R.

AU - Nicholson, Brenda P.

AU - Hande, Kenneth

AU - Blanke, Charles

AU - Johnson, David

AU - Cohen, Alan

PY - 1999

Y1 - 1999

N2 - This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.

AB - This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1) determine the maximum tolerated dose and dose-limiting toxicities of UFT plus calcium folinate (Orzel) administered three times per day for 21 days in combination with paclitaxel; and 2) define the appropriate dose for phase H testing. Thus far, 14 patients have been accrued to three dose levels. Two patients developed dose-limiting toxicities at dose level 3. One patient experienced grade 3 hypotension. A second patient experienced grade 3 vomiting, grade 4 diarrhea, and severe hand-foot syndrome. Two partial responses and one complete response have been observed. Early trends suggest that this regimen is active in metastatic breast cancer and is well tolerated. Completion of this study is anticipated in 1999.

UR - http://www.scopus.com/inward/record.url?scp=0032775864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032775864&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 69

EP - 70

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 SUPPL.

ER -